Published on in Vol 12 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/42032, first published .
An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study

An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study

An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study

Journals

  1. Capriglia F, Burgess T, Bandmann O, Mortiboys H. Clinical Trial Highlights: Modulators of Mitochondrial Function. Journal of Parkinson's Disease 2023;13(6):851 View
  2. Hamatani T, Atsuta N, Sano F, Nakamura R, Hayashi Y, Sobue G. ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2024;25(3-4):388 View
  3. Rodríguez‐Valdez G, Martínez‐Cerda M, Mejía‐Reyes J, Tapia‐Juárez M, Olmos‐Orizaba E, Cortés‐Rojo C, Cortés‐García C, Contreras‐Celedón C, Solorio‐Alvarado C, Chacón‐García L. A Metastable Semiquinone Molecular Switch Modulated by Ascorbate/O2: A Study from a System Far‐From‐Equilibrium to Biological Assays in Mitochondria. ChemBioChem 2024;25(18) View

Books/Policy Documents

  1. Firdous S, Pal S, Mandal S, Sindhu R. Antioxidants. View